The European Medicines Agency’s advisory group, Committee for Human Medicinal Products (CHMP), has concluded that GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) antibody COVID-19 treatment, sotrovimab, can be used.
The opinion covers confirmed COVID-19 in adults and adolescents who don’t require supplemental oxygen therapy and are at risk of progressing to severe COVID-19.
EMA said an interim analysis of the infusion indicated that sotrovimab reduced the risk of hospitalization for more than 24 hours or death by 85% compared with placebo.
Hospitalization for more than 24 hours or death occurred in 1% (3 out of 291) of patients who received sotrovimab and 7% (21 out of 292) of those who received placebo.
The companies also submitted an emergency use authorization application for the mAb to the FDA, and Health Canada is also reviewing it.
Price Action: VIR shares are down 0.09% at $45.11, and GSK stock is down 0.40% at 38.87 during the market session on the last check Friday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.